![Robert Wassman](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Dr. Robert Wassman, MD, Medical Geneticist is as Chief Medical Adviser at Lineagen, Inc. Dr. Wassman has more than 30 years of experience in executive roles.
He was a Co-Founder of Good Start Genetics and served as its Chief Medical Officer.
He served as President and Chief Medical Officer of Celula, Inc. He served as the Chief Medical Officer of Rosetta Genomics, Ltd. from October 2012 to September 18, 2015.
Prior to joining Lineagen, Dr. Wassman served in various positions focused on advancing the translation and delivery of cutting-edge diagnostic technology into clinical service.
| Sociétés | Poste | Début |
|---|---|---|
Bluestone Venture Partners LLC
 Bluestone Venture Partners LLC Investment ManagersFinance BlueStone Venture Partners invests in middle market companies located in the United States primarily in Arizona, New Mexico, Oklahoma and Texas. The firm focuses on companies operating in the fields of medical devices, diagnostics, digital health and life science research tools. It provides financing for seed, early and growth stage capital requirements with an investment size ranging from USD 0.25 to 1 million. It acts as lead investor and takes seat on the board of directors. | Consultant / Advisor | - |
| Sociétés | Poste | Fin |
|---|---|---|
Celula, Inc.
 Celula, Inc. Medical/Nursing ServicesHealth Services Provides diagnostic testing services | President | - |
Actives
Inactives
Sociétés cotées
Entreprise privées
| Entreprise privées | 2 |
|---|---|
Celula, Inc.
Celula, Inc. Medical/Nursing ServicesHealth Services Provides diagnostic testing services | Health Services |
Bluestone Venture Partners LLC
Bluestone Venture Partners LLC Investment ManagersFinance BlueStone Venture Partners invests in middle market companies located in the United States primarily in Arizona, New Mexico, Oklahoma and Texas. The firm focuses on companies operating in the fields of medical devices, diagnostics, digital health and life science research tools. It provides financing for seed, early and growth stage capital requirements with an investment size ranging from USD 0.25 to 1 million. It acts as lead investor and takes seat on the board of directors. | Finance |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national
